Arkolith/Insider Trading/ORKA/Form 4

Dambkowski Carl

DirectorOruka Therapeutics, Inc. (ORKA) · full profile →Form 4 · filed May 22, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$6.2M
Net Open-Market Flow
-$6.2M
Transactions
9
6 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 21, 2026Option exercise(M)39K$6.84$265K155K
May 21, 2026Option exercise(M)12K$7.80$93K167K
May 21, 2026Option exercise(M)12K$11.77$137K179K
May 21, 2026Sell(S)38K$58.43$2.2M140K
May 21, 2026Sell(S)53K$59.10$3.2M87K
May 21, 2026Sell(S)13K$59.97$794K74K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 21, 2026Option exercise(M)39K—$033K
May 21, 2026Option exercise(M)12K—$011K
May 21, 2026Option exercise(M)12K—$06K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000907654-26-000043) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML